- Home
- HYB vs STTK Comparison
HYB vs STTK Comparison
Compare HYB & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYB
- STTK
- Stock Information
- Founded
- HYB 1987
- STTK 2016
- Country
- HYB United States
- STTK United States
- Employees
- HYB N/A
- STTK N/A
- Industry
- HYB Investment Managers
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- HYB Finance
- STTK Health Care
- Exchange
- HYB Nasdaq
- STTK Nasdaq
- Market Cap
- HYB 194.0M
- STTK 173.6M
- IPO Year
- HYB 1999
- STTK 2020
- Fundamental
- Price
- HYB $8.32
- STTK $3.64
- Analyst Decision
- HYB
- STTK Strong Buy
- Analyst Count
- HYB 0
- STTK 3
- Target Price
- HYB N/A
- STTK $10.67
- AVG Volume (30 Days)
- HYB 39.6K
- STTK 152.9K
- Earning Date
- HYB 01-01-0001
- STTK 11-07-2024
- Dividend Yield
- HYB 6.67%
- STTK N/A
- EPS Growth
- HYB N/A
- STTK N/A
- EPS
- HYB N/A
- STTK N/A
- Revenue
- HYB N/A
- STTK $4,123,999.00
- Revenue This Year
- HYB N/A
- STTK $164.45
- Revenue Next Year
- HYB N/A
- STTK N/A
- P/E Ratio
- HYB N/A
- STTK N/A
- Revenue Growth
- HYB N/A
- STTK 380.09
- 52 Week Low
- HYB $6.23
- STTK $1.33
- 52 Week High
- HYB $7.41
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- HYB 77.79
- STTK 51.46
- Support Level
- HYB $8.13
- STTK $3.37
- Resistance Level
- HYB $8.34
- STTK $3.75
- Average True Range (ATR)
- HYB 0.07
- STTK 0.23
- MACD
- HYB -0.01
- STTK 0.07
- Stochastic Oscillator
- HYB 76.34
- STTK 78.85
About HYB New America High Income Fund Inc. (The)
New America High Income Fund Inc is a diversified, closed‐end management investment company. Its investment objective is to provide high current income while seeking to preserve stockholder capital by investing in a diversified portfolio of high-yield fixed-income securities. The Fund has a leveraged capital structure. The fund invests in fixed-maturity corporate debt securities that are rated less than the investment grade. Its portfolio of investment consists of investments in different sectors such as energy, financial, cable operators, healthcare, and others.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.